[1] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedauiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004
URL
|
[2] |
Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4(3):288-293. doi: 10.1038/mi.2011.10.
doi: 10.1038/mi.2011.10
pmid: 21451503
|
[3] |
Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer, 2011, 2:363-368. doi: 10.7150/jca.2.363.
doi: 10.7150/jca.2.363
pmid: 21716717
|
[4] |
Zhou Y, Chen CL, Jiang SW, et al. Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncoimmunology, 2018, 8(2):e1528411. doi: 10.1080/2162402X.2018.1528411.
doi: 10.1080/2162402X.2018.1528411
URL
|
[5] |
Kolloli A, Singh P, Rodriguez GM, et al. Effect of iron supplementation on the outcome of non-progressive pulmonary Mycobacterium tuberculosis infection. J Clin Med, 2019, 8(8):1155. doi: 10.3390/jcm8081155.
doi: 10.3390/jcm8081155
URL
|
[6] |
Wu J, Wang S, Lu C, et al. Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection. Tuberculosis(Edinb), 2017, 102:68-75. doi: 10.1016/j.tube.2016.06.001.
doi: 10.1016/j.tube.2016.06.001
|
[7] |
Sun Q, Wei W, Sha W. Potential Role for Mycobacterium tuberculosis Specific IL-2 and IFN-γ Responses in Discriminating between Latent Infection and Active Disease after Long-Term Stimulation. PLoS One, 2016, 11(12):e0166501. doi: 10.1371/journal.pone.0166501.
doi: 10.1371/journal.pone.0166501
URL
|
[8] |
Lin PL, Flynn JL. CD8 T cells and Mycobacterium tuberculosis infection. Semin Immunopathol, 2015, 37(3):239-249. doi: 10.1007/s00281-015-0490-8.
doi: 10.1007/s00281-015-0490-8
URL
|